Innovative Industrial Properties (IIPR) delivered a clean headline beat for the third quarter. AFFO of $1.96 per share topped the $1.74 consensus by 8.3% and cleared the $1.81 Earnings Whisper number. Revenue of $64.92 million beat the $61.21 million consensus by 6.1%. AFFO grew 8.9% year over year and rose sharply from $1.83 in the second quarter, a genuine sequential acceleration. Revenue grew only 0.4% from a year ago. That gap between earnings and top-line growth is the central tension. IIPR is increasingly earning its money from high-yield life science financing and collections from troubled tenants, not from a growing cannabis rent roll.

The quality of the beat deserves scrutiny. Management said the quarter included roughly $0.15 per share of past-due rent recoveries from Battle Green, 4Front, PharmaCann and Parallel, and called them non-recurring. Strip that out and AFFO lands almost exactly on the whisper number. Revenue was also supported by $3.8 million of security deposits applied on Cannabist and Parallel properties. The deposits for the five defaulted tenants are now exhausted, so that cushion will not repeat. The bigger structural change sits below the operating line:

• Interest and other income jumped to $14.3 million from $4.4 million a year ago, including $10.4 million from the IQHQ investments.
• Interest expense rose to $11.8 million from $4.5 million.

On a GAAP basis, net income attributable to common stockholders was essentially flat at $0.99 per share versus $0.97. That is a reminder that the AFFO improvement is not translating into much bottom-line expansion.

The operating story on the call was better than the numbers alone suggest. Leasing was the strongest in the company's history:

• 604,000 square feet signed across six properties in the quarter.
• A 270,000-square-foot Pennsylvania lease after quarter end, contingent on license transfer approvals.
• Year-to-date gross leasing of 1.3 million square feet, against 339,000 for all of 2025.
• Another 446,000 square feet of agreements in the pipeline.
• Tentative replacement tenants for all three remaining 4Front assets, which represent 7.1% of annualized contractual rent and are expected to transition by year end or early 2027.
• Battle Green's Ohio lease reassigned to a Vireo affiliate, with a Vireo guaranty.

The defaults, however, keep coming. IIPR terminated 16 leases covering 1.2 million square feet and regained possession of properties from Parallel, PharmaCann and Cannabist. That leaves roughly 800,000 square feet of vacancy, about two-thirds of it in two Florida assets, and management cited a 6-to-18-month timeline before rent commences on re-leased space. Bulls can point to a healthier Florida market, where 22 new licenses were issued and sales rose 20% year over year in July. Even so, the earnings drag from vacant space will precede the benefit.

The forward catalyst is life science. Total commitments have roughly doubled to about $545 million, from $270 million. The new pieces are:

• A $245 million Alewife Park mezzanine loan yielding about 15.8%, with a 14% floor. About $111 million was funded at close and the rest is due through late 2027.
• An additional $30 million of IQHQ preferred equity.
• An option on a further $155 million tranche of Alewife notes.

Management projects life science at roughly 26% of income once funded, and the fourth quarter should carry a fuller Alewife contribution. Management's tone was notably more expansive, with appetite for more of this business. The trade-off is concentration: much of that exposure sits with a single counterparty, IQHQ.

The balance sheet is where bears have legitimate ammunition. Leverage has risen quickly:

• Net debt to adjusted EBITDA reached 2.1x, up from 1.7x in the second quarter and 1.1x in the first.
• Liquidity fell to $142 million from $300 million.
• The $87.5 million revolver was extended only 90 days, to January 2027.
• New capital came from a 9.25% Series B preferred, which is expensive funding even against mid-teens loan yields.

The payout ratio improved to 97% and the $1.90 dividend was maintained. With one-time recoveries rolling off, however, coverage remains tight. No formal guidance was provided, and broader DEA rescheduling remains unresolved.

Investor sentiment improved meaningfully but remains negative, rising from -0.41 to -0.24. Price action has not followed. At $54.40, shares are down 5.9% since the open after the August report and sit about 1.2% below the $55.05 200-day moving average. Earnings Whispers price and AVWAP trend readings remain negative, consistent with a market that has been reluctant to reward the pivot.

The bottom line is that IIPR's beat looks larger than it is. Recoveries management itself labeled non-recurring flattered it, and exhausted security deposits remove a revenue backstop. Still, record leasing and a fast-growing, high-yield life science book give the company a credible path to replacing lost cannabis rent. The next few quarters hinge on three things: converting the leasing pipeline into paying rent, absorbing the Florida vacancies, and refinancing the revolver without further straining a balance sheet that has levered up quickly.